Valuation: Imugene Limited

Market Cap 37.43M 26.17M 22.99M 21.38M 19.62M 36.86M 2.52B 254M 99.17M 1.24B 98.25M 96.13M 4.28B P/E 2026 *
-0.77x
P/E 2027 * -1.14x
Enterprise Value 37.13M 25.96M 22.8M 21.21M 19.46M 36.56M 2.5B 252M 98.38M 1.23B 97.46M 95.36M 4.25B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
96.9%
Yield 2026 *
-
Yield 2027 * -
1 day-2.17%
1 week-3.23%
Current month-21.74%
1 month-10.00%
3 months-28.00%
6 months-74.65%
Current year-75.34%
1 week 0.09
Extreme 0.089
0.1
1 month 0.09
Extreme 0.089
0.16
Current year 0.09
Extreme 0.089
0.41
1 year 0.09
Extreme 0.089
0.46
3 years 0.09
Extreme 0.089
5.1
5 years 0.09
Extreme 0.089
21.25
10 years 0.09
Extreme 0.089
21.25
Manager TitleAgeSince
Chief Executive Officer - 01/11/2016
Director of Finance/CFO - 04/03/2025
Chief Tech/Sci/R&D Officer - 01/09/2023
Director TitleAgeSince
Chairman 70 31/10/2012
Director/Board Member - 28/03/2018
Director/Board Member 66 23/04/2019
Date Insider Type Main position Quantity % Market Cap.
12/19/25 A Fiscal year

Director

14,706 0.0047%
12/19/25 A Free

Director

14,706 0.0047%
12/19/25 A Free

Director

14,706 0.0047%
Change 5-day change 1-year change 3-year change Capi.($)
-2.17%-3.23%-66.67%-97.12% 26.17M
+1.07%-3.49%-3.35%+10.44% 46.86B
+0.25%+1.65%+399.22%+634.87% 40.23B
-0.27%+4.45%+11.81%+65.64% 36.23B
+0.35%+0.87%+4.46%-10.16% 34.72B
+3.14%+1.02%+4.76%+40.92% 27.89B
-0.73%+11.84%+34.39%+134.36% 16.79B
+0.47%-2.74% - - 16.74B
+0.42%-5.52%-3.43%+9.03% 13.12B
-2.68%-2.49%-11.36%-33.61% 12.7B
Average -0.01%+0.42%+41.09%+83.82% 24.53B
Weighted average by Cap. +0.48%+0.91%+74.40%+136.25%

Financials

2026 *2027 *
Net sales - -
Net income -56.51M -39.52M -34.71M -32.28M -29.62M -55.65M -3.81B -383M -150M -1.87B -148M -145M -6.47B -42.79M -29.92M -26.28M -24.44M -22.43M -42.14M -2.88B -290M -113M -1.42B -112M -110M -4.9B
Net Debt -300K -210K -184K -171K -157K -295K -20.2M -2.03M -795K -9.93M -788K -771K -34.34M -1M -699K -614K -571K -524K -985K -67.34M -6.78M -2.65M -33.11M -2.63M -2.57M -114M
Logo Imugene Limited
Imugene Limited is a clinical-stage immune-oncology company. It is engaged in developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Its platform technology seeks to harness and promote the body’s immune system against cancerous tumors. Its product pipeline includes an off-the-shelf (allogeneic) cell therapy CAR T drug Azer-Cel (azercabtagene zapreleucel) which targets CD19 to attack blood cancer. Its pipeline includes an Oncolytic Virus and B-Cell Immunotherapies aimed at treating a variety of cancers in combination with standard of care drugs and immunotherapies. Its lead candidate is a chimeric vaccinia (pox) virus known as CF33, which is a combination of genomic sequences from multiple vaccinia virus strains to generate a new, safer and more potent virus. Its Chimeric antigen receptor (CAR)-engineered T cells (CAR T) are T cells redirected against tumors through engineered expression of CARs.
Employees
15
Date Price Change Volume
24/07/26 A$0.0900 -2.17% 5,685,537
23/07/26 A$0.0920 -1.08% 2,153,720
22/07/26 A$0.0930 -1.06% 806,243
21/07/26 A$0.0940 +2.17% 668,201
20/07/26 A$0.0920 -1.08% 1,094,738
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.0900AUD
Average target price
0.3067AUD
Spread / Average Target
+240.74%

Quarterly revenue - Rate of surprise